

Premier Sponsor



CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides lifesaving products to patients in more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit [CSLBehring.com/Vita](https://www.CSL.com/Vita) and follow us on [Twitter.com/CSL](https://www.CSL.com/Twitter). For more information about CSL Limited, visit www.CSL.com

Major Sponsors



AVATAR

[Avatar Brokers](#) is a specialist brokerage, working with developers of innovative solutions for key world issues. We provide a level of unmatched excellence in broking to our clients through experience, longevity and specialised negotiating skills; we see our role as a risk advisor, expert buyer and claims manager.


Avatar acts for 36% of the ASX listed Pharmaceuticals, Biotechnology and Life Sciences sector, and 70% of our client base is derived from technology, life sciences, green energy and related service providers. We are passionate about supporting our clients and offer a nimble, personable and collaborative approach to our work, helping our clients achieve world-leading scientific and technological advancements.



At Radium Capital we believe businesses with R&D should have access to capital when they need it. So, we created the Radium Advance to enable innovators to unlock their tax refunds sooner.

Through Radium Advances we provide quick, easy and early access to up to 80% of your expected R&D tax incentive refund - in just a few business days.

Radium Advances are non-dilutive and are available as one-off cash injections, or can be used strategically throughout the year. The more you use Radium Advances, the more your R&D benefits.



For example, under a quarterly Advance model, for the same expenditure, you can boost your R&D spend by 50% or reduce outlay by 33%.

Radium Capital is Australia's market leader in R&D financing. Since launching in 2017, we have helped hundreds of clients on their innovation journeys and have deployed over one-third of a billion dollars in Australian R&D financing.

Find out how businesses are using Radium Advances to accelerate growth, attract other sources of funding and smooth cash flow at radiumcapital.com.au



Almac Clinical Services, part of the Almac Group, currently provide services to over 600 Pharmaceutical and Biotech companies worldwide including 18 of the top 20 global pharma companies. Guided by our extensive clinical supply experience and expertise, we are recognised as one of the leading, multi-

faceted, global solution providers within the niche and complex market of clinical trial supply. Utilising our best in house Supply Chain Management expertise, custom designed services and software solutions, we offer the most flexible approach to support the delivery of your global clinical trial from protocol right through to patient delivery. To learn how we can support your clinical study, visit almacgroup.com.


Signature Sponsor



Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities.

We bring together approximately 28,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.



Supporting Sponsors



Brooker Consulting is proud to play a vital role in executive talent acquisition, enhancing the life science industry's capacity for growth and profitability. This includes the health, research and commercialisation sectors, as well as professional associations, universities and service providers. We also offer interim talent solutions for short term executive requirements, and a range of Executive Consulting services. Call Lesley Lightfoot or Jeremy Wurm on 03 9602 1666 or email career@brookerconsulting.com.au or visit us at www.brookerconsulting.com.au




[Hemideina](#) is a hearing solutions company, focused on improving treatment for moderate-to-profound deafness, with the Hera Wireless Implant. Hemideina's disruptive solution, inspired by insect hearing systems, aims to remove lifestyle barriers and improve hearing outcomes for patients. As a female-founded company, we are proud supporters of the BioMelbourne Network and their support and encouragement of women in the biomedical sector, through their Connecting Women Lunch and the Women in Leadership Awards.



[Phillips Ormonde Fitzpatrick](#) is a leading Australian intellectual property firm. Our professionals work with innovators at the cutting edge of advancements in science and technology with bringing products and services to market. We embrace diversity and proudly recognise women in leadership, and are delighted to be an inaugural sponsor of the BioMelbourne Women's luncheon.



[Starpharma](#) is a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for DEP[®] drug delivery, and a number of marketed products including Viralze[™] and VivaGel BV[®]. Through innovative research and development, Starpharma has built a deep portfolio of high-value products on-market as well as having three internal clinical-stage assets, which have the potential to improve patient health worldwide. Starpharma has a number of licensing and research collaboration partnerships with leading, global companies, including AstraZeneca, Merck & Co. Inc,



and Chase Sun. Starpharma's marketed products have been licensed in >160 countries, are registered in >45 countries and available for sale in Europe, Asia, A/NZ and the Middle East.



WEHI is where the world's brightest minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancers, infectious and immune diseases, developmental disorders and healthy ageing.

WEHI brings together diverse and creative people with different experience and expertise to solve some of the world's most complex health problems. With partners across science, health, government, industry and philanthropy, we are committed to long-term discovery, collaboration and translation. At WEHI, we are brighter together.

Find out more at www.wehi.edu.au



Nucleus Network is Australia's largest and only multi-site dedicated Phase 1 clinical research organization with facilities located in two of Australia's largest cities, Melbourne and Brisbane, as well as a third location in Minneapolis in the USA.

Operating over 200 dedicated beds combined, our three sites in Australia (Melbourne and Brisbane) and the USA (Minneapolis) are co-located in world-leading medical research and biotech precincts; the Alfred Hospital in Melbourne, the Royal Brisbane and Women's Hospital in Brisbane, and Medical Alley in Minnesota.

These precincts provide our internationally recognized, in-house Principal Investigators and scientists with unique access to highly specialized ancillary services for the conduct of complex Phase 1 clinical trials.

Over two decades, Nucleus Network has conducted over 1,000 Phase 1 clinical trials for Biotechnology and Pharmaceutical Companies from across the globe. Averaging 100 trials per year, approximately 50% of which are true first-in-human, we have extensive experience in the conduct of early phase study designs in healthy volunteers and patient populations.

With over half of our workforce, including company management positions held by women, Nucleus Network actively supports gender equality and greatly values the contribution and leadership of women in the life sciences industry. As such we are proud to be supporting BioMelbourne Network's Connecting Women Lunch in 2022.

For more about how Nucleus Network are assisting our sponsors in "Advancing medicine, improving lives", please visit www.nucleusnetwork.com